Keyphrases
Placebo-controlled Trial
100%
Randomized Double-blind
100%
Chronic Obstructive Pulmonary Disease
100%
Tadalafil
100%
Quality of Life
71%
Placebo
42%
Treatment Group
42%
Exercise Capacity
42%
Placebo Groups
42%
Dyspepsia
42%
Exercise Efficiency
42%
Scotland
28%
6-minute Walk Distance (6MWD)
28%
Phosphodiesterase Type 5 Inhibitors
28%
Beneficial Effects
14%
Standardized Questionnaire
14%
Moderate to Severe
14%
Pneumonia
14%
Intention-to-treat
14%
Headache
14%
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
14%
Between-group Difference
14%
Transient Ischemic Attack
14%
Short Form 36 (SF-36)
14%
Ruptured Abdominal Aortic Aneurysm (rAAA)
14%
Proton Pump Inhibitors
14%
Pulmonary Hypertension
14%
Block Size
14%
Selected Populations
14%
St. George's Respiratory Questionnaire
14%
Patient Study
14%
Chief Scientist
14%
Group Allocation
14%
Facial Flushing
14%
Idiopathic Pulmonary Arterial Hypertension
14%
Pulmonary Vasodilation
14%
Severe Chronic Obstructive Pulmonary Disease
14%
Medicine and Dentistry
Placebo
100%
Chronic Obstructive Pulmonary Disease
100%
Tadalafil
100%
Quality of Life
62%
Exercise
37%
Stomach Acid
37%
Phosphodiesterase V Inhibitor
25%
Pulmonary Hypertension
25%
Intention-to-Treat Analysis
12%
Walking Distance
12%
Transient Ischemic Attack
12%
Short Form 36
12%
Vasodilatation
12%
Abdominal Aortic Aneurysm
12%
Congestive Heart Failure
12%
Proton-Pump Inhibitor
12%
Headache
12%
St. George Respiratory Questionnaire
12%
4 Chloro 3',6' Dimethyl 2,2' Iminodibenzoic Acid
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Chronic Obstructive Lung Disease
100%
Tadalafil
100%
Stomach Acid
37%
Phosphodiesterase V Inhibitor
25%
Pulmonary Hypertension
25%
Headache
12%
Proton Pump Inhibitor
12%
Congestive Heart Failure
12%
Transient Ischemic Attack
12%
Abdominal Aortic Aneurysm
12%
4 Chloro 3',6' Dimethyl 2,2' Iminodibenzoic Acid
12%